December 30, 2003 11:20:00 (ET)

RENO, Nev., Dec 30, 2003 (BUSINESS WIRE) -- At Lifeline BioTechnologies Inc.'s (NQB: LBTT) year-end annual management meeting, company executives reviewed the accomplishments during the year against the objectives it set out to complete in 2003. Jim Holmes, CEO, announced that this year will stand out in the company's history as a turning point in the development of a number of key elements of the company's strategic plan.

Holmes commented on the following major accomplishments: Although the introduction of First Warning System(TM) into the Chinese market was indeed a milestone, just finding the proper business partner in this distant market presents its own challenges. Even though progress has been slower than originally anticipated due to Chinese government regulations and potential price barriers, patient testing continues, and sales could occur in the coming new year.

NippleScope(TM) received the CE Mark in late 2003, which allows the company to initiate sales efforts in Europe and others markets where the CE is accepted. Lifeline BioTechnologies is planning its initial introduction of the NippleScope(TM) at the annual Cancer Congress in Munich, Germany in March of 2004. Dr. Kefah Mokbel, the company's lead investigator in Europe, will be presenting a lecture on his experience with Lifeline's NippleScope(TM) during this meeting. Initial sales in Europe are expected in first and second quarters of 2004; application for FDA clearance of this scope has been accelerated. Initial domestic (U.S.) sales of the NippleScope(TM) may occur as early as the second quarter of 2004.

Testing of Lifeline's ovarian scope has not moved forward as quickly as anticipated. Management is seeking alternative test sites for this promising, albeit very early stage, medical product.

Lifeline secured the Arthronet exclusive distribution agreement earlier this year. Initial product sales have begun through its national distribution, and are expected to increase in 2004.

The prospects for 2004 are promising with important areas as a priority. The company continues to seek financing and is in preliminary discussions with a major Wall Street firm; other prospective funding sources are also being considered.

The year-end accounting is being wound up and the financial audit is expected to be underway in January.

Dr. William H. Reeves, president and founder of Lifeline BioTechnologies, commented concerning Lifeline's flagship product, the First Warning System(TM) (FWS). "The FWS is a process that is designed to assist in the early detection of breast cancer, and the research group and I feel confident that we are coming closer to a resolution, and an understanding, of the role of the physiologic behavior of those benign breast lesions, which become cancers. Our success will undoubtedly be a breakthrough in medicine and breast cancer detection. Once resolved, the FWS will advance to the final phase clinical trials."

Concluding, the entire management team wishes its friends and shareholders a very safe and happy new year.

quote:

---

Originally posted by chill:
Hi Anna,
Oh! Thanks. Do you know a good place where I can read about what a pink sheet stock is?
Thanks again,
chill

---

I then frantically go to the news page thinking that maybe something big is being released and its the release below. If you look in the disclaimer the company that released this is paid to do so.

InvestSource Inc.: InvestSource Alert: ELIN, LBTT, RBAKQ, JDSU, ADSX
12/31/03

Dec 31, 2003 (M2 PRESSWIRE via COMTEX) --
Elinear Incorporated (OTC: ELIN) traded up .12 in yesterdays trading session after announcing they will be featured in the Investor's Business Daily newspaper on Jan. 2.

Lifeline Biotechnologies Incorporated (OTC: LBTT), Redback Networks Incorporated (Nasdaq: RBAKQ),
JDS Uniphase Corp (Nasdaq: JDSU) and Applied Digital Solutions Inc (Nasdaq: ADSX). InvestSource has put an alert on these stocks.

InvestSource alerts, for those who like to stay on top of the markets. New 52-week highs signaled that the market might be due for a stall with the S&P 500 already up 26% for the year. Not a lot of volatility as most buyers found the sidelines following yesterday's substantial run-up. Stay Alert, and have a safe and prosperous New Year!

ABOUT InvestSource:

InvestSource is a full-service communications and investor relations firm that specializes in achieving full stock valuations for public companies. Our American economy depends on our emerging growth companies of today! InvestSource is the firm that produces timely, bold research on small/micro cap companies with upside potential. As Wall Street Gems appear, InvestSource will feed the street with many 1st to market opportunities based on a foundation of sound analysis with the management teams of these exploding companies.

Efficiency in stock selection just got easier. InvestSource. Grow from today's research - Today. For more information on the companies InvestSource works with, go to the corporate website at www.investsource.us.

All material herein was prepared by InvestSource based upon information believed to be reliable. The information contained herein is not guaranteed by InvestSource to be accurate, and should not be considered to be all-inclusive.

The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. InvestSource is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities mentioned herein. InvestSource often receives compensation for services by one or more of the companies mentioned.

InvestSource has been compensated 6000 shares of restricted stock by Elinear Inc. for services rendered. To view full disclaimers, go to www.investsource.us (disclaimers).

InvestSource's affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event of a rise in value.

InvestSource will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

CONTACT: InvestSource Inc. Tel: +1 800 352 1788

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

(C)1994-2003 M2 COMMUNICATIONS LTD

[/QUOTE]